Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.50 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.50 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.50 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17593254 | 0.95 | IDO1 (0.53) | IDO1HPGDCYP11B1CYP11B2TDP1 | |
| SCHEMBL22921868 | 0.91 | TSHR (0.58) | KMT2ATSHREPHX2CYP4F2CYP4A11 | |
| SCHEMBL516422 | 0.89 | IDO1 (0.65) | IDO1HPGDCYP11B1CYP11B2MEN1 | |
| SCHEMBL17009102 | 0.88 | IDO1 (0.48) | IDO1HPGDCYP11B1CYP11B2PLAAT3 | |
| Hydrochloric Acid SCHEMBL16062033 | 0.87 | IDO1 (0.63) | IDO1HPGDCYP11B1CYP11B2MEN1 | |
| SCHEMBL10583619 | 0.87 | TSHR (0.50) | KMT2ATSHREPHX2CYP4F2CYP4A11 | |
| SCHEMBL5568348 | 0.86 | TSHR (0.48) | KMT2ATSHREPHX2CYP4F2CYP4A11 | |
| SCHEMBL27700759 | 0.86 | TSHR (0.48) | KMT2ATSHREPHX2CYP4F2CYP4A11 | |
| SCHEMBL12508639 | 0.84 | TSHR (0.50) | L3MBTL1TSHREPHX2CYP4F2CYP4A11 | |
| SCHEMBL1866015 | 0.84 | CYP4A11 (0.50) | HPGDTDP1KMT2ATSHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288683-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-18 | — | — | US | disclosed |
| EP-4519272-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| WO-2024098361-A1 | ARTIFICIAL NUCLEIC ACID MOLECULE | 斯微(上海)生物科技股份有限公司 | 2024-05-16 | — | — | WO | disclosed |
| WO-2023215449-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230295200-A1 | STAT5 and STAT6 Inhibitors and Uses Thereof | UNIV MICHIGAN (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230263742-A1 | A LIPID | Stemirna Therapeutics Co., Ltd. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230263742-A1 | A LIPID | Stemirna Therapeutics Co., Ltd. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230251264-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. | 2023-08-10 | — | — | US | disclosed |
| CN-107567443-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-28 | — | — | CN | disclosed |
| CN-115925679-A | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-07 | — | — | CN | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160298031-A1 | MESOGENIC MEDIA AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-20160289561-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-10-06 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-20150218150-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-08-06 | — | — | US | disclosed |
| US-20150086551-A1 | Novel Therapeutic Agents | CRYSTAL BIOPHARMACEUTICAL LLC | 2015-03-26 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| WO-2010070076-A1 | ALKANOIC ACID DERIVATIVES AND THEIR THERAPEUTIC USE AS HDAC INHIBITORS | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2010-06-24 | — | — | WO | disclosed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | IDO1 4170/4885HPGD 2068/4885CYP11B1 149/4885 |
| US-20230263742-A1 | A LIPID | CETP, PLIN1, AUP1 | IDO1 3301/4885HPGD 3269/4885CYP11B1 2020/4885 |
| US-20160289561-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | IDO1 3094/4885HPGD 4238/4885CYP11B1 1613/4885 |
| US-20230251264-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | IDO1 4349/4885HPGD 2346/4885CYP11B1 4851/4885 |
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | IDO1 929/4885HPGD 1260/4885CYP11B1 107/4885 |
| US-20230295200-A1 | STAT5 and STAT6 Inhibitors and Uses Thereof | STAT6, STAT5B, STAT5A | IDO1 1636/4885HPGD 3521/4885CYP11B1 1699/4885 |
| US-20150218150-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, BAK1 | IDO1 218/4885HPGD 653/4885CYP11B1 1032/4885 |
| US-20150086551-A1 | Novel Therapeutic Agents | HDAC1, HDAC11, HDAC5 | IDO1 405/4885HPGD 809/4885CYP11B1 1906/4885 |
| US-20250288683-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2L1, BCL2, BCL2L10 | IDO1 1503/4885HPGD 2106/4885CYP11B1 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.